Short answer
Celldex Therapeutics, Inc. (CLDX) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $15,000 (down 97.8% year over year) with net income of −$79M.
Q1 2026 key financials · XBRL
- Revenue
- $15,000
- −97.8% YoY
- Net income
- −$79M
- Operating margin
- -562900.0%
- EPS (diluted)
- −$1.18
- −45.7% YoY
Source: XBRL data from the Celldex Therapeutics, Inc. (CLDX) Q1 2026 10-Q on SEC EDGAR. USD.
Celldex Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue figures and YoY comparison not provided in supplied MD&A
- R&D expense $73.001M vs $52.614M YoY, up $20.387M
- Barzolvolimab R&D $62.164M vs $39.703M YoY, largest program increase
- Cash position, operating cash flow, and capital deployment figures not provided
- CSU Phase 3 enrollment complete with topline data expected fourth quarter 2026
Risk Factors
- No material changes to 10-K risk factors filed February 25, 2026
- No newly triggered risk factor identified for the quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Celldex Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.